antiquity
03-11-2002, 11:28 AM
Raymedica Announces New Patent for Surgical Instrumentation; Device to Aid In The Implantation of the PDN(R) Prosthetic Disc Nucleus
MINNEAPOLIS, March 11 /PRNewswire/ -- Raymedica, Inc., a development-stage medical device manufacturer, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent for surgical instrumentation to be used with its PDN(R) Prosthetic Disc Nucleus technology. The new patent is titled "Method and Apparatus for Dilation of Spinal Disc Anulus."
"Over the past few years, Raymedica engineers have worked closely with a small group of international spine surgeons to develop instruments useful in the implantation of the PDN device," said Tony Phillips, Raymedica president and chief executive officer. "From this collaborative effort, we have introduced several novel surgical instruments which enable surgeons to implant the PDN device more easily and with less trauma to the patient's spinal anatomy than would occur in traditional spine surgery. The new instrumentation was developed specifically for the PDN device, but could benefit other spine surgery procedures."
Raymedica now has 12 U.S. and 16 international patents on its proprietary PDN device and ancillary instruments with an additional two U.S. and 26 international patents pending.
The PDN device is comprised of a hydrogel material designed to replace the function of a failed spinal disc nucleus. To treat low-back pain, a pair of PDN devices is implanted in the center of the spinal disc. The devices are designed to support the bones of a patient's spine while allowing for more normal flexibility and movement than spinal fusion, the current established surgical treatment, in which adjacent vertebrae are fused together.
The PDN device is commercially available in Europe and other international regions, but is not yet approved in the United States. More than 600 patients worldwide have received PDN implants. Raymedica is pursuing marketing approval from the U.S. Food and Drug Administration and recently received approval to begin a second round of U.S. clinical evaluations.
About Raymedica, Inc.
Raymedica, privately held and based in Minneapolis, developed the PDN prosthetic disc nucleus for the surgical treatment of low-back pain that does not respond to conservative care. Back pain is the second most common reason patients seek medical care in the United States, with more than 1.5 million people requiring surgical treatment annually. More information about Raymedica and the PDN device is available on the Internet at http://www.raymedica.com
MINNEAPOLIS, March 11 /PRNewswire/ -- Raymedica, Inc., a development-stage medical device manufacturer, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent for surgical instrumentation to be used with its PDN(R) Prosthetic Disc Nucleus technology. The new patent is titled "Method and Apparatus for Dilation of Spinal Disc Anulus."
"Over the past few years, Raymedica engineers have worked closely with a small group of international spine surgeons to develop instruments useful in the implantation of the PDN device," said Tony Phillips, Raymedica president and chief executive officer. "From this collaborative effort, we have introduced several novel surgical instruments which enable surgeons to implant the PDN device more easily and with less trauma to the patient's spinal anatomy than would occur in traditional spine surgery. The new instrumentation was developed specifically for the PDN device, but could benefit other spine surgery procedures."
Raymedica now has 12 U.S. and 16 international patents on its proprietary PDN device and ancillary instruments with an additional two U.S. and 26 international patents pending.
The PDN device is comprised of a hydrogel material designed to replace the function of a failed spinal disc nucleus. To treat low-back pain, a pair of PDN devices is implanted in the center of the spinal disc. The devices are designed to support the bones of a patient's spine while allowing for more normal flexibility and movement than spinal fusion, the current established surgical treatment, in which adjacent vertebrae are fused together.
The PDN device is commercially available in Europe and other international regions, but is not yet approved in the United States. More than 600 patients worldwide have received PDN implants. Raymedica is pursuing marketing approval from the U.S. Food and Drug Administration and recently received approval to begin a second round of U.S. clinical evaluations.
About Raymedica, Inc.
Raymedica, privately held and based in Minneapolis, developed the PDN prosthetic disc nucleus for the surgical treatment of low-back pain that does not respond to conservative care. Back pain is the second most common reason patients seek medical care in the United States, with more than 1.5 million people requiring surgical treatment annually. More information about Raymedica and the PDN device is available on the Internet at http://www.raymedica.com